vimarsana.com

Page 80 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Flywire Corporation Closes IPO and Full Exercise of Underwriters Option to Purchase Additional Shares

Flywire Corporation Closes IPO and Full Exercise of Underwriters Option to Purchase Additional Shares
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRaymond jamesWilliam blairBroadridge financial solutionsJp morgan securitiesExchange commissionProspectus departmentFlywire corporationTelsey advisory groupGoldman sachs coRamirez co incCitigroup global markets incWall streetNasdaq global select marketBofa securities

Centessa Announces Pricing of Initial Public Offering

Centessa Announces Pricing of Initial Public Offering
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomMary clark shabnam bashirDan budwickJennifer porcelliMorgan stanleyExchange commission onProspectus departmentStrategic communicationsEquity syndicate prospectus departmentGoldman sachs coEvercore groupCentessa pharmaceuticalsMorgan stanley coDepositary shares

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency News provided by Share this article Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ( Calliditas ) today announced that the company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN). The submission is based on positive data from Part A of the NefIgArd pivotal Phase 3 study, a randomized, double-blind, placebo-controlled, international multicenter study designed to evaluate the efficacy and safety of Nefecon compared to placebo in 200 adult patients with IgAN. The study achieved its primary endpoint of proteinuria reduction compared to placebo, and also showed a renal protective effect by way of stabilization of eGFR at 9 months.

United statesMarie galayExchange commissionEuropean medicines agencyCommittee for human medicinal productsNasdaq stockholmMarketing authorisation applicationIga nephropathyAccelerated assessmentHuman medicinal productsNasdaq global select marketPrivate securities litigation reform actCalliditas therapeuticsHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Centessa raises $330M in third largest biotech IPO this year

BioPharma

United kingdomMoncef slaouiPalladio biosciencesCapella biosciencePearlriver bioSaurabh sahaCentessa pharmaceuticalsRecursion pharmaceuticalsDive briefGeneral atlanticVida venturesJanus henderson investorsSana biotechnologyRecursion pharmaceuticalsOrexia therapeuticsBiopharma dive

Investegate |First Advantage Announcements | First Advantage: First Advantage Files Registration Statement for Proposed Initial Public Offering

First Advantage Files Registration Statement for Proposed Initial Public Offering ATLANTA, May 28, 2021 (GLOBE NEWSWIRE) First Advantage Corporation, a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to a proposed initial public offering of its common stock. First Advantage has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol “FA”. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

North carolinaUnited statesRoberts ryanBroadridge financial solutionsCapital marketsBarclays capital incJp morgan securitiesFirst advantage corporationExchange commissionProspectus departmentRamirez co incR seelaus coFirst advantage files registration statementProposed initial publicAdvantage corporationNasdaq global select market

vimarsana © 2020. All Rights Reserved.